Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1305 in Advanced/Metastatic Solid Tumors
NCT05438329Phase 2Active, not recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Jul 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of DB-1305 in solid tumor (30 arms), sponsored by Duality Biotherapeutics. Primary endpoints: Dose-Limiting Toxicities, Treatment Emergent Adverse Events and 4 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
DB-1305
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05438329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438329.